A 4% Solution of Bovine Serum Albumin May Be Used in Place of Factor VIII:C Deficient Plasma in the Control Sample in the Nijmegen Modification of the Bethesda Factor VIII:C Inhibitor Assay

Thromb Haemost 2002; 88(02): 362-364
DOI: 10.1055/s-0037-1613214

Letters to the Editor

Schattauer GmbH

Bert Verbruggen

¹Central Laboratory for Haematology, University Medical Centre St Radboud Nijmegen, The Netherlands

,

Waander van Heerde

¹Central Laboratory for Haematology, University Medical Centre St Radboud Nijmegen, The Netherlands

,

Irena Novákovà

²Department of Haematology, University Medical Centre St Radboud Nijmegen, The Netherlands

,

David Lillicrap

³Kingston General Hospital & Queen’s University, Kingston, Ontario, Canada

,

Alan Giles

³Kingston General Hospital & Queen’s University, Kingston, Ontario, Canada

References
1 Bert Verbruggen, Irena Novakova, Hans Wessels, Jan Boezeman, Marijke van den Berg, Eveline Mauser-Bunschoten. The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability. Thromb Haemost 1995; 73: 247-51.
2 Giles AR, Verbruggen B, Rivard G, Teitel J, Walker I. A detailed comparison of the performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Hemophilia A Population of Canada. Thromb Haemost 1998; 79: 872-5.
3 Bert Verbruggen, Alan Giles, John Samis, Kitty Verbeek, Ewald Mensink, Irena Novákovà. The Type of Factor VIII Deficient Plasma used influences the performance of the Nijmegen Modification of the Bethesda Assay for Factor VIII Inhibitors. Thromb Haemost 2001; 86: 1435-9.
4 Van den Brink EN, Turenhout EAM, Davies J, Bovenschen N, Fijnvandraat K, Ouwehand WH, Peters M, Voorberg J. Human Antibodies with Specificity for the C2 domain of factor VIII are derived from germline genes. Blood 2000; 95: 558-63.